We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Unremarkable antibody responses against various infectious agents after inoculation with the BNT162b2 COVID‐19 vaccine.
- Authors
Kozawa, Kei; Miura, Hiroki; Kawamura, Yoshiki; Higashimoto, Yuki; Ihira, Masaru; Yoshikawa, Tetsushi
- Abstract
Abbreviations BAU binding antibody unit COVID-19 coronavirus disease 2019 EBV Epstein-Barr virus ELISA enzyme-linked immunosorbent assay EU enzyme-linked immunosorbent assay unit FHA filamentous hemagglutinin IgG immunoglobulin G mRNA messenger ribonucleic acid PT pertussis toxin SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccines are highly effective in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and disease onset.1 The mRNA contained in vaccines can activate innate immune responses and is also translated into protein antigens in the cytoplasm, which can induce strong humoral and cell-mediated immune responses.2 Since mRNA vaccines can be rapidly designed and developed after identifying the sequence of an emerging infectious agent, this vaccine platform is ideal for producing vaccines against emerging infectious diseases. SARS-CoV-2 S protein, N protein, and membrane protein all cross-react with thyroid peroxidase.9 In addition, polyclonal B cell activation10 and bystander activation enhance cytokine production and expansion of autoreactive B and T cells. Two doses of the BNT162b2 vaccine did not change antibody titers against the 9 microorganisms (11 antibodies) at all.
- Subjects
RUBELLA; ANTIBODY formation; MEDICAL personnel; SARS-CoV-2; COVID-19 vaccines; CHICKENPOX vaccines; VACCINATION; BACTERIAL vaccines
- Publication
Journal of Medical Virology, 2022, Vol 94, Issue 10, p4583
- ISSN
0146-6615
- Publication type
Case Study
- DOI
10.1002/jmv.27895